CohBar discoveries 'a shocker to scientists' says CEO

cohbar_big

Californian aging specialist CohBar (Nasdaq: CWBR) is using mitochondrial science to treat diseases, but chief executive Steven Engle doesn’t rule out offering a “cure for aging” at some point.

Asked whether the firm could find itself developing products for healthy people to take, with the specific purpose of extending healthy lifespan, he says: “Yes, I think that's possible.”

He points to the example of metformin, a commonly used compound for diabetics, which he says “actually has positive effects on things like cancer.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology